LA JOLLA—Associate Professor Janelle Ayres has been awarded $1.8 million over two years by the NOMIS Foundation to study health as an active process in which microbes—including the trillions of microorganisms that call the human body home—initiate interactions that promote the health of the host.
LA JOLLA—For the eighth consecutive time, the Salk Institute’s strong financial health and continuing commitment to accountability and transparency have earned it a coveted 4-star (out of 4 stars) rating from Charity Navigator, America’s largest independent charity and nonprofit evaluator.
LA JOLLA—Salk Professors Joanne Chory, Joseph Ecker and Rusty Gage have once again been named to the Highly Cited Researchers list by Clarivate Analytics (formerly Thomson Reuters). The list selects researchers for “exceptional research performance” demonstrated by the production of multiple highly cited papers that rank in the top 1 percent by citations for field and year. Additionally, among the 4,058 researchers named as Highly Cited, Ecker is one of 194 researchers appearing in two separate categories: “plant and animal science,” as well as “molecular biology and genetics.”
LA JOLLA—Nicola Allen, an assistant professor in Salk’s Molecular Neurobiology Laboratory, has received a five-year, $2.5 million Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative (CZI), as part of a $51.95 million effort launching the CZI Neurodegeneration Challenge Network. This new network brings together experimental scientists from diverse research fields—neuroscience, cell biology, biochemistry, immunology and genomics—along with computational biologists and physicians, to understand the underlying causes of disorders such as Alzheimer’s, Parkinson’s, Huntington’s disease and ALS.
LA JOLLA—Embryonic stem cells (ESCs) are the very definition of being full of potential, given that they can become any type of cell in the body. Once they start down any particular path toward a type of tissue, they lose their unlimited potential. Scientists have been trying to understand why and how this happens in order to create regenerative therapies that can, for example, coax a person’s own cells to replace damaged or diseased organs.
LA JOLLA—It might seem like fruit flies would have nothing in common with computers, but new research from the Salk Institute reveals that the two identify novel information in similar ways. The work, which appeared in Proceedings of the National Academy of Sciences (PNAS) on December 3, 2018, not only sheds light on an important neurobiological problem—how organisms detect new odors—but could also improve algorithms for novelty detection in computer science.
LA JOLLA—Salk Professor and Howard Hughes Medical Investigator Ronald Evans, who is also director of Salk’s Gene Expression Laboratory, has been a named a 2018 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society. In particular, the AAAS acknowledges his discoveries on steroid and orphan receptor signaling, revealing a “treasure trove” of both known and novel branches of physiology, metabolism and disease, according to the citation.
LA JOLLA—For most, the time spent staring at screens—on computers, phones, iPads—constitutes many hours and can often disrupt sleep. Now, Salk Institute researchers have pinpointed how certain cells in the eye process ambient light and reset our internal clocks, the daily cycles of physiological processes known as the circadian rhythm. When these cells are exposed to artificial light late into the night, our internal clocks can get confused, resulting in a host of health issues.
LA JOLLA—Old age is the greatest risk factor for many diseases, including Alzheimer’s disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New Salk research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.
LA JOLLA—A team of Salk Institute researchers led by President Rusty Gage has been awarded $19.2 million over eight years by the American Heart Association-Allen Initiative in Brain Health and Cognitive Impairment to investigate mechanisms underlying Alzheimer’s disease and aging-related cognitive decline and uncover new therapies. This bold venture will comprehensively analyze interactions between five areas key to brain health: proteins, genes, metabolism, inflammation and epigenetics.
LA JOLLA—Long thought to suppress cancer by slowing cellular metabolism, the protein complex AMPK also seemed to help some tumors grow, confounding researchers. Now, Salk Institute researchers have solved the long-standing mystery around why AMPK can both hinder and help cancer.
LA JOLLA—Clodagh O’Shea, a professor in Salk’s Molecular and Cell Biology Laboratory and a Howard Hughes Medical Institute Faculty Scholar, has been selected as a recipient of The Paul G. Allen Frontiers Group’s Allen Distinguished Investigator (ADI) program. She will be awarded $1.5 million over three years to conduct research into how DNA and its associated proteins (known collectively as chromatin) are packaged in the nucleus of cells. The work has implications for better understanding not only a range of diseases but also the fundamentals of human biology.
LA JOLLA—Salk Professor Melvin Cohn, titan of immune system biology and a pioneering researcher in the field of gene regulation, passed away on October 23, 2018, in San Diego, California, at the age of 96.
LA JOLLA—The emerging technology of sonogenetics—a technique where cells are controlled by sound—offers the potential to one day replace pharmaceutical drugs or invasive surgical treatments for neurological conditions like epilepsy, Parkinson’s disease or posttraumatic stress disorder.
LA JOLLA—Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory, has been named one of TIME magazine’s 50 most influential people in healthcare for his scientific innovations in addressing the shortage of human organs for transplant. The list, which is curated by TIME’s health reporters and editors, recognizes people who changed the state of healthcare in America this year, and bear watching for what they do next.
LA JOLLA—When we’re born, our brains have a great deal of flexibility. Having this flexibility to grow and change gives the immature brain the ability to adapt to new experiences and organize its interconnecting web of neural circuits. As we age, this quality, called "plasticity," lessens.
LA JOLLA—As part of its Keeping It Modern initiative, the Getty Foundation has awarded the Salk Institute a $200,000 grant to support the conservation of Salk’s celebrated concrete facades. The grant project will take place over the next five years. The announcement is part of more than $1.7 million in architectural conservation grants announced by the foundation in 2018 for 11 significant 20th century buildings.
LA JOLLA—The Salk Institute is honored to welcome Dannielle Engle back to Salk as an assistant professor in the Salk Cancer Center. She is currently a senior fellow at Cold Spring Harbor Laboratory in New York, where she focuses on the early detection and treatment of pancreatic cancer. Engle conducted research in the lab of Salk Professor Geoffrey Wahl for six years as part of her doctoral program at UC San Diego.
LA JOLLA—Associate Professor Janelle Ayres has been awarded a 2018 NIH Director’s Pioneer Award by the National Institutes of Health for her innovative research into host-pathogen interactions that promote the health of the host.
LA JOLLA—Approximately 1.25 million Americans are living with type 1 diabetes (T1D), with an additional 40,000 people newly diagnosed every year. T1D is an autoimmune disease that destroys insulin-producing pancreatic islet cells. Insulin is a hormone that allows sugar (glucose) to enter cells to produce energy. Without insulin, blood sugar accumulates, causing toxic side effects. Despite active research, T1D has no cure. While treatments, including daily insulin injections, are available, managing the disease remains challenging, and poorly controlled T1D can lead to blindness, organ failure and other health issues.